Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat

Core Insights - Akebia Therapeutics Inc. has officially established a rare kidney disease pipeline, focusing on two main product candidates: AKB-097 and praliciguat [1][3] - The company aims to position Vafseo as the standard treatment for anemia in dialysis patients while simultaneously developing a robust pipeline for rare kidney conditions [1] Product Details - Vafseo is an oral treatment for anemia due to chronic kidney disease in adults on dialysis for at least three months, approved in 37 countries, and stimulates endogenous erythropoietin production [2] - AKB-097, previously known as ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to target complement activation at the organ level, potentially reducing infection risks and dosing frequency [3] Financial Transactions - Akebia entered into an Asset Purchase Agreement with Q32 Bio Inc. to acquire global rights to AKB-097, paying an upfront fee of $7 million, with an additional $3 million due six months post-closing [3]